Display options
Cite
Brown PA, Angel JB. Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. J Immune Based Ther Vaccines. 2005;3(1):3doi: 10.1186/1476-8518-3-3.
Brown, P. A., & Angel, J. B. (2005). Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. Journal of immune based therapies and vaccines, 3(1), 3. https://doi.org/10.1186/1476-8518-3-3
Brown, Pierre Antoine, and Angel, Jonathan B. "Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection." Journal of immune based therapies and vaccines vol. 3,1 (2005): 3. doi: https://doi.org/10.1186/1476-8518-3-3
Brown PA, Angel JB. Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. J Immune Based Ther Vaccines. 2005 May 18;3(1):3. doi: 10.1186/1476-8518-3-3. PMID: 15904525; PMCID: PMC1164429.
Copy Download .nbib Format: NLM
Share it on

J Immune Based Ther Vaccines. 2005 May 18;3(1):3. doi: 10.1186/1476-8518-3-3.

Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection.

Journal of immune based therapies and vaccines

Pierre Antoine Brown, Jonathan B Angel

Affiliations

  1. Department of Medicine, University of Ottawa, 501 Smyth, Box 210, Ottawa, Canada, K1H 8L6. [email protected].

PMID: 15904525 PMCID: PMC1164429 DOI: 10.1186/1476-8518-3-3

Abstract

The HIV/AIDS epidemic continues to spread despite more than 20 years of significant research and major advances in its treatment. The introduction of highly active antiretroviral therapy in recent years has significantly improved disease treatment with a dramatic impact in HIV/AIDS associated morbidity and mortality in countries which have access to this therapy. Despite these advances, such therapies are imperfect and other therapeutic modalities, including immune-based therapies, are being actively sought. Potential benefits of immune-based therapies include: 1) the improvement of HIV-specific immunity to enhance control of viral replication, 2) the improvement of other aspects of host immunity in order to prevent or delay the development of opportunistic infections and 3) the potential to purge virus from cellular reservoirs which are sustained despite the effects of potent antiretroviral therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been studied as one of these immune-based therapies. Several randomized, controlled trials have demonstrated benefits of using GM-CSF as an adjunct to conventional anti-retroviral therapy, although such benefits have not been universally observed. Individual studies have shown that GM-CSF increases CD4+ T cells counts and may be associated with decreased plasma HIV RNA levels. There is limited evidence that GM-CSF may help prevent the emergence of antiretroviral drug resistant viruses and that it may decrease the risk of infection in advanced HIV disease. Despite its high costs and the need to be administered subcutaneously, encouraging results continue to emerge from further studies, suggesting that GM-CSF has the potential to become an effective agent in the treatment of HIV infection.

References

  1. Vaccine. 1996 Sep;14(13):1199-204 - PubMed
  2. AIDS Res Hum Retroviruses. 2004 Aug;20(8):794-806 - PubMed
  3. J Virol. 1998 Jun;72(6):4962-9 - PubMed
  4. N Engl J Med. 1987 Sep 3;317(10):593-8 - PubMed
  5. AIDS. 2000 Mar 10;14(4):387-95 - PubMed
  6. AIDS. 2003 Jul 4;17(10):1487-92 - PubMed
  7. AIDS. 1997 Oct;11(12):1453-61 - PubMed
  8. Expert Rev Anti Infect Ther. 2003 Jun;1(1):83-96 - PubMed
  9. Nat Med. 1999 May;5(5):512-7 - PubMed
  10. Blood. 1996 Nov 1;88(9):3474-81 - PubMed
  11. N Engl J Med. 1997 Sep 11;337(11):725-33 - PubMed
  12. J Infect Dis. 2000 Nov;182(5):1531-5 - PubMed
  13. J Gen Virol. 1999 Jan;80 ( Pt 1):217-23 - PubMed
  14. Blood. 1992 Aug 15;80(4):995-1003 - PubMed
  15. JAMA. 1998 Mar 11;279(10):756-61 - PubMed
  16. N Engl J Med. 1998 Mar 26;338(13):853-60 - PubMed
  17. Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S169-77 - PubMed
  18. J Clin Oncol. 1991 May;9(5):802-8 - PubMed
  19. Science. 1997 Nov 14;278(5341):1291-5 - PubMed
  20. AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):129-38 - PubMed
  21. Curr Opin Hematol. 2000 May;7(3):168-73 - PubMed
  22. New Microbiol. 1997 Oct;20(4):345-50 - PubMed
  23. Blood. 1990 Mar 15;75(6):1215-9 - PubMed
  24. J Viral Hepat. 1999 Sep;6(5):405-9 - PubMed
  25. Blood. 1991 Dec 15;78(12):3148-54 - PubMed
  26. AIDS. 1999 Oct 1;13(14):1933-42 - PubMed
  27. J Infect Dis. 2003 Dec 15;188(12):1804-14 - PubMed
  28. J Infect Dis. 1999 Oct;180(4):1064-71 - PubMed
  29. Blood. 1998 Jun 15;91(12):4752-60 - PubMed
  30. Science. 1997 Nov 14;278(5341):1295-300 - PubMed
  31. J Viral Hepat. 1996 May;3(3):149-53 - PubMed
  32. J Chemother. 1996 Jun;8(3):214-20 - PubMed
  33. Lancet. 1998 Feb 21;351(9102):543-9 - PubMed
  34. AIDS. 1999 Apr 16;13(6):633-43 - PubMed
  35. Infection. 1997 Mar-Apr;25(2):129 - PubMed
  36. JAMA. 2000 Nov 1;284(17):2193-202 - PubMed

Publication Types